Authors
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar Kristensen, Christian Jackisch, Florence Joly, Chris Brown, Nathalie Le Fur, Andreas Du Bois
Publication date
2010/7/10
Journal
Journal of clinical oncology
Volume
28
Issue
20
Pages
3323-3329
Publisher
American Society of Clinical Oncology
Description
Purpose
This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).
Patients and Methods
Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m2) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m2) every 3 weeks for at least 6 cycles. Primary end point was progression-free survival (PFS); secondary end points were toxicity, quality of life, and overall survival.
Results
Overall 976 patients were recruited. With median follow-up of 22 …
Total citations
Scholar articles
E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist… - Journal of clinical oncology, 2010